Taking rivaroxaban is a risk factor for acute kidney disease and disorders in patients with coronary heart disease or non-valvular atrial fibrillation

被引：1
|
作者：
李文 [1 ]
机构：
[1] Dept Nephrol,Xuanwu Hosp, Capital Med Univ
来源：
China Medical Abstracts (Internal Medicine) | 2020年 / 37卷 / 04期
关键词：
AKD; Taking rivaroxaban is a risk factor for acute kidney disease and disorders in patients with coronary heart disease or non-valvular atrial fibrillation;
D O I：
暂无
中图分类号：
R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）]; R541.75 [];
学科分类号：
1002 ; 100201 ;
摘要：
Objective To observe the risk of acute kidney disease and disorders (AKD) in patients with coronary heart disease or non-valvular atrial fibrillation who were taking rivaroxaban for the first time in our hospital.
引用
收藏
页码：228 / 229
页数：2
相关论文
共 50 条
  • [21] Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis
    Miao, Benjamin
    Sood, Nitesh
    Bunz, Thomas J.
    Coleman, Craig, I
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) : 328 - 335
  • [22] The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease
    McCormack, T.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (08) : 707 - 709
  • [23] Thromboembolic Risk of Imaging-Confirmed Coronary Artery Disease Without Myocardial Infarction in Patients With Non-Valvular Atrial Fibrillation
    Cho, Min Soo
    Lee, Kyusup
    Choi, Kee-Joon
    Do, Ungjeong
    Kim, Yu-na
    Hwang, Jongmin
    Kim, Jun
    Nam, Gi-Byoung
    Kim, You-Ho
    [J]. CIRCULATION, 2017, 136
  • [24] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    [J]. CIRCULATION, 2014, 130
  • [25] Thromboembolic risk of imaging-confirmed coronary artery disease without myocardial infarction in patients with non-valvular atrial fibrillation
    Choi, K. -J.
    Cho, M. S.
    Do, W. J.
    Kim, Y. N.
    Kim, J.
    Nam, G. B.
    Kim, Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 : 615 - 615
  • [26] Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Ferreira, Jorge
    [J]. REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 141 - 148
  • [27] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [28] Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Xiao-qin Liu
    Yu-fei Zhang
    Hong-yan Ding
    Ming-ming Yan
    Zheng Jiao
    Ming-kang Zhong
    Chun-lai Ma
    [J]. Acta Pharmacologica Sinica, 2022, 43 : 2723 - 2734
  • [29] Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Liu, Xiao-qin
    Zhang, Yu-fei
    Ding, Hong-yan
    Yan, Ming-ming
    Jiao, Zheng
    Zhong, Ming-kang
    Ma, Chun-lai
    [J]. ACTA PHARMACOLOGICA SINICA, 2022, 43 (10) : 2723 - 2734
  • [30] The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation
    Shimokawa, Hiroaki
    Yamashita, Takeshi
    Uchiyama, Shinichiro
    Kitazono, Takanari
    Shimizu, Wataru
    Ikeda, Takanori
    Kamouchi, Masahiro
    Kaikita, Koichi
    Fukuda, Koji
    Origasa, Hideki
    Sakuma, Ichiro
    Saku, Keijiro
    Okumura, Yasuo
    Nakamura, Yuichiro
    Morimoto, Hideo
    Matsumoto, Naoki
    Tsuchida, Akihito
    Ako, Junya
    Sugishita, Nobuyoshi
    Shimizu, Shogo
    Atarashi, Hirotsugu
    Inoue, Hiroshi
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 258 : 126 - 132
12345